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Asbestos-related cancers such as malignant mesothelioma and lung cancer are an important issue in the world. There are many
conﬂicts concerning economical considerations and medical evidence for these cancers and much confusion regarding details of
the pathological mechanisms of asbestos-induced cancers. For example, there is uncertainty concerning the degree of danger
of the iron-absent chrysotile compared with iron-containing crocidolite and amosite. However, regarding bad prognosis of
mesothelioma, medical approaches to ensure the recognition of the biological eﬀects of asbestos and the pathological mechanisms
of asbestos-induced carcinogenesis, as well as clinical trials to detect the early stage of mesothelioma, should result in better
preventions and the cure of these malignancies. We have been investigating the immunological eﬀects of asbestos in relation to the
reduction of tumor immunity. In this paper, cellular and molecular approaches to clarify the immunological eﬀects of asbestos are
described, and all the ﬁndings indicate that the reduction of tumor immunity is caused by asbestos exposure and involvement in
asbestos-induced cancers. These investigations may not only allow the clear recognition of the biological eﬀects of asbestos, but
also present a novel procedure for early detection of previous asbestos exposure and the presence of mesothelioma as well as the
chemoprevention of asbestos-related cancers.
1.Introduction
The fact that inhaled asbestos causes malignant mesothe-
lioma and lung cancer is an enormous medical and social
problem. Canada’s decision to expand asbestos mining and
export to developing countries in which asbestos has not
been banned is unsettling [1]. People are sometimes inﬂuen-
ced by economical forces even though they know many
peoplehavesuﬀeredfrommalignantdiseasescausedbythese
minerals, and their decisions appear to be made for ﬁnancial
reasons.
In Japan, the asbestos issue erupted in the summer of
2005 [2–4]. Residents were suddenly informed that asbestos,
which was used in large amounts from the early 1950s
up to the early 1990s in Japan with a maximum usage
of approximately 352,000 tons in 1974, caused malignant
mesothelioma (MM). Residents that lived near the asbestos
handling manufacturer Kubota Corporation, in Amazasaki
City, Hyogo Prefecture, developed MM. They had never
worked in the asbestos-handling manufacture industry.
In addition, medical information regarding MM induced
anxiety in the Japanese people, since the prognosis is very
poor, and there is no certain way to detect the cancer in
the very early stage of the disease. Furthermore, people
c o u l dn o tr e m e m b e rb e i n ge x p o s e dt oa s b e s t o s3 0t o4 0
years ago. To reduce the anxieties of the Japanese peo-
ple, epidemiological analyses regarding the Amagasaki area
proceeded, and clinical and basic research was conducted
on the biological eﬀects of asbestos and early detection
of mesothelioma. It is in this context that the authors2 Clinical and Developmental Immunology
became involved in the project “Comprehensive Approach
onAsbestos-RelatedDiseases”,supportedbythe“SpecialCo-
ordination Funds for Promoting Science and Technology”
(Dr. Takemi Otsuki, Department of Hygiene, Kawasaki
Medical School, Kurashiki, Japan) from 2006 to 2010. In
this project, a case and clinical specimen registration system
was established. A feasibility clinical trial was established and
involved a combined trimodality therapy using anticancer
chemotherapy with cisplatin and pemetrexed, following by
extrapleural pneumonectomy and postoperative radiation
therapyforearly-stagemesotheliomapatients[5,6].Further-
more, early detection procedures were developed using
serum or pleural eﬀusions to measure soluble mesothelin-
related peptide (SMRP) and other markers such as osteo-
pontin, vascular endothelial growth factor (VEGF) and angi-
opoietin-1 [7–9],aswellasproceduresfordetectionofcircu-
lating mesothelioma cells and circulating epithelial cells us-
ing peripheral blood [10, 11].
For the basic research, the project “Comprehensive Ap-
proach on Asbestos-Related Diseases” included three sub-
groups: (1) analyses of cellular and molecular characteristics
using mesothelioma cell lines, (2) investigation of asbestos-
inducedcarcinogenesisusingananimalmodel,and(3)study
of the immunological eﬀects of silica/asbestos.
The ﬁrst subgroup explored novel tumor suppres-
sor gene(s) in mesothelioma cells and found that the
serine/threonine-protein kinase (LATS2) gene is inactivated
in approximately one-third of mesothelioma cell lines and
is a candidate for a novel tumor suppressor in MM [12]. In
addition, they found the possibility that the Yes-associated
protein (YAP) involved the NF2/Merlin-hippo signaling
pathway and that LATS2 may constitutively dephosphorylate
and act as an oncogene to bind with the TEAD transcription
factor to enhance the cell cycle and resistance to apoptosis
[13]. In addition, mesothelioma-speciﬁc epigenetic proﬁles
were identiﬁed for diﬀerential diagnosis with lung adenoma-
tous cancers [14].
The second subgroup conﬁrmed the importance of iron
in asbestos-induced carcinogenesis. Findings showed that
not only iron-containing crocidolite and amosite, but also
chrysotile asbestos caused mesothelioma when these mate-
rials were injected into the peritoneal region of a rat. Even
individual rats having mesothelioma caused by the injec-
tion of iron-absent chrysotile showed numerous depositions
of iron in the spleen, liver, and kidney. In addition, add-
ing nitrilotriacetate (NTA) to chrysotile-injected rats in-
duced the acceleration of mesothelioma formation, suggest-
ing the critical participation of iron for asbestos-induced
carcinogenesis even for chrysotile. Although the detailed
mechanisms of this phenomenon are now being explored,
the binding ability of chrysotile to hemoglobin and other
proteins and the induced hemolysis is a concern [15–
18]. Moreover, the importance of a homozygous deletion
of CDKN2A/2B was found in rat mesothelioma with the
suggestion that this deletion seems to be fundamental for
the development of mesothelioma, since these genes are also
known to be homozygously deleted in human mesothelioma
[19].
We have performed the third subtheme concerning the
“immunological eﬀects of silica/asbestos”. In this paper, we
introduce our ﬁndings and considerations regarding in-
volvement of reduced tumor immunity caused by asbestos
exposure to immunocompetent cells as the basic condition
in asbestos-exposed people who may develop MM.
2. Immunological Effects of Asbestos
Asbestos comprises a set of six naturally occurring sil-
icate minerals (chrysotile as Serpentine and crocidolite,
amosite, actinolite, anthophyllite, and tremolite as Amphi-
bole) exploited commercially for their desirable physical
properties. They all have in common their asbestiform
structure, possessing long (having more than 1:3 aspect
ratio, usually approximately 1:20) and thin ﬁbrous crystals
[20, 21]. Silica (SiO2) certainly aﬀects the human immune
system, because people exposed to silica not only suﬀer from
respiratory disorders known as silicosis, but also experience
complications with autoimmune disorders such as rheuma-
toidarthritis(knownasCaplan’ssyndrome),systemicsclero-
sis, systemic lupus erythematosus, and antineutrophil cyto-
plasmic antibody- (ANCA-) related vasculitis/nephritis [22–
27]. We have, therefore, been exploring the mechanisms
involved in silica-induced dysregulation of autoimmunity
using case peripheral blood specimens. We had found that
there is dysregulated expression of the CD95/Fas molecule,
which is very important for the survival of self-recognizing
T cell clones. Additionally, analyses of Fas and Fas-related
molecules in silicosis patients suggested that there are two
populationsofTcells:oneisthelong-termsurvivingpopula-
tions probably including self-recognizing clones, and the
other is a population repeating apoptosis caused by silica
and recruiting from the bone marrow [28, 29]. In addition,
our recent studies regarding CD4+25+ and forkhead box
P3 (FoxP3)+ regulatory T cells (Treg) suggested that (1)
silica activates both responder T cells (Tresp) and Treg,
(2) Tresp chronically-activated by silica becomes CD4+25+
(and programmed cell death-1 (PD-1) + as an activated
cell marker) expressers, (3) Treg activated by silica express
higherCD95/FasandaresensitivetoFas-mediatedapoptosis,
and (4) after the ongoing progression of these events, the
composition of the peripheral CD4+25+ fraction in silicosis
patients changes to reﬂect a loss of Treg and a gain of
activated Tresp, and this reduction of Treg function results
in activation of autoimmunity in silicosis patients [30–32].
Since silica inﬂuences the human immune system, its
mineral silicate, an asbestos, may also have an eﬀect.
As we considered silica’s immunological eﬀects from the
complicationsofsilicosisandautoimmunediseases,themost
important complication of asbestos-exposed people is the
occurrence of malignant disease such as MM and lung
cancer. In addition, some epidemiological studies suggested
a relationship between asbestos exposure and other cancers
of the gastrointestinal tract, larynx, kidney, liver, pancreas,
ovary, and hematopoietic systems [33–35]. Thus, if asbestos
aﬀects the immune system, a reduction of tumor immunity
may result and then make people exposed to asbestosClinical and Developmental Immunology 3
sensitive to the development of malignancies. Of course,
asbestos itself possesses carcinogenic activities. As shown in
Figure 1, asbestos ﬁbers having iron (or even chrysotile as
mentioned above) produce reactive oxygen/nitrogen species
(ROS/RNS) causing DNA damage to nearby cells, and
ﬁbers are sometimes directly inserted into the cells and
injure chromosomes, while retained ﬁbers may adsorb other
carcinogens on their surface (known as an asbestos body)
[15, 16, 18, 36, 37]. As a result, speciﬁc DNA alterations may
result, such as inactivation (mostly homozygous deletion) of
p16INK4a/p14ARF, NF2/Merlin, and LATS2, and the activation
ofYAP asmentionedabove[12,13].However,itisdiﬃcultto
explain why the development of mesothelioma requires 30 to
40 years, and how asbestos-exposed people possess sensitive
features for other cancers.
We have been considering that asbestos may aﬀect
immunocompetent cells such as CD4+ Tresp, Treg, Th17 T
cells, CD8+ cytotoxic T cells (CTL), monocyte-macrophage,
natural killer (NK) cells, natural killer T (NKT) cells, and
dendritic cells (DC). Firstly, to observe the eﬀects of low-
dose and continuous exposure to asbestos (we initially chose
chrysotile because this is the most frequently used asbestos
in Japan, and our investigations suggested it was not carcino-
genic), we employed a human adult leukemia/lymphoma
virus-1 (HTLV-1) immortalized polyclonal T cell line, MT-
2[ 38, 39]. In the next part of this paper, analysis of asbestos
exposure to the MT-2 cell line is documented.
3. Transientand ContinuousExposureto
Asbestos on aHumanTCellLine
Initially, the cellular alteration of MT-2 cells exposed to tran-
sient and high-dose chrysotile was observed to compare var-
ious published investigations showing the ability of asbestos
exposure to induce ROS production and mitochondrial-
pathway-dependent apoptosis in normal alveolar epithelial
cells and mesothelial cells, which are the target cells of
asbestos-induced carcinogenesis. As shown on the left side
of Figure 2, transient and relatively high-dose exposure (25–
50μg/mL, not likely to comprise adhesive cells such as
alveolar epithelial or mesothelial cells, since we are using
suspendedcells,andthus,μg/mLwasusedinsteadofμg/cm2)
caused production of ROS as measured by production of
O2
− using ﬂow cytometry, phosphorylation of proapoptotic
molecules in the mitogen-activated protein kinase (MAPK)
pathway such as p38 and c-Jun N-terminal kinase (JNK),
release of cytochrome-c from mitochondria to the cytosol,
BAX overexpression, cleavage of caspase-9 and -3, and
thereafter the appearance of apoptosis [40]. These ﬁndings
resembled the eﬀects of asbestos on alveolar epithelia and
mesothelial cells [41–44].
We then conducted a trial to establish a low-dose
and continuous exposure cell line model by adding 5 or
10μg/mL of chrysotile (doses which cause apoptosis in
less than half of cells exposed transiently) to the MT-2
cell culture. After more than eight months exposure with
monthly monitoring for the occurrence of apoptosis, and
when these cells were re-exposed to ﬁbers one week after
beingreleasedfromcontinuouslyexposedchrysotile,anMT-
2 subline which showed resistance to chrysotile-induced
apoptosis had been established. As shown on the right side of
Figure 2, the continuously exposed subline of MT-2 showed
activation of Src-family kinase, increased expression and
production of interleukin (IL)-10, phosphorylation of signal
transducer and activator of transcription 3 (STAT3) with
overexpression of BCL-2 (located downstream of STAT3)
[45, 46]. In addition, transforming growth factor (TGF)-β
was upregulated [47, 48]. Actually, we had established three
independent continuously exposed sublines to chrysotile B
and three other sublines exposed to chrysotile A. The altered
gene expression of these six continuously exposed sublines in
comparison with the original MT-2 cell line was very similar,
and the cellular and molecular characteristics of these cell
lines in regard to tumor immunity with the ex vivo chrysotile
exposure model using freshly isolated peripheral blood
CD4+ T cells derived from healthy donors was investigated
and conﬁrmed using peripheral blood specimens derived
from asbestos-exposed patients such as patients with pleural
plaque (PP) or MM.
Chemokinereceptor,CXCchemokinereceptor(CXCR)3,
expression and relation with interferon (IFN)-γ.
Using the above-mentioned MT-2 original cell line and
the continuously exposed chrysotile sublines, molecules
related to tumor immunity were investigated. For example,
CXCR3 expression was a focus of investigations, since
CXCR3downregulationinsublineswasdetectedincompari-
son with the original line using cDNA microarray analysis. It
is known that CXCR3 expression and IFN-γ production are
induced by T-cell activation and lead to the enhancement of
antitumor immune function [49, 50].
From ﬁndings using the MT-2 cell line model, as shown
in Figure 3(a), all six continuously exposed sublines showed
reduced CXCR3 expression on their surface and mRNA
expression levels with reduced production and expression
of IFN-γ. Production of the Th1-type CXCR3 ligand
CXCL10/IP10 was also signiﬁcantly reduced in all six con-
tinuously exposed sublines when compared with the original
line. In addition, another Th1-type chemokine, CCL4/MIP-
1β mRNA, was also expressed at low levels in all six sublines
comparedwiththeMT-2originallineaspreviouslyreported.
However, CCR5, the Th1-type receptor for CCL4/MIP-1β,
was not reduced signiﬁcantly through mRNA expression
in MT-2Rsts cells. These results indicated that continuous
exposure of MT-2 original cells to asbestos altered the
expression of Th1-related chemokines (CXCL10/IP10 and
CCL4/MIP-1β) and chemokine receptors (CXCR3) [51].
Thereafter,wetriedtodeterminewhetherfreshlyisolated
human peripheral CD4+ T cells show a similar alter-
ation ex vivo when proliferation is maintained by IL-2-
containing medium in the presence of chrysotile as shown
in Figure 3(b). After 40 days of coculture supplemented with
IL-2 in the presence or absence of chrysotile, cell surface
CXCR3 expression decreased in a dose-dependent manner.
Thus, we examined cell surface expression of CXCR3 and
CCR5 in CD4+ T cells derived from six healthy donors, since
both receptors are preferentially expressed in Th1/eﬀector
T cells. The expression of CXCR3 was signiﬁcantly reduced4 Clinical and Developmental Immunology
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Figure 1: Schematic model showing mechanisms of asbestos-induced carcinogenesis and genomic/epigenetic changes found in mesothelio-
ma cells and the relationship of the immunological eﬀects of asbestos in regard to reduced tumor immunity.
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T cell line, MT-2.
following exposure to 10μg/mL of chrysotile for 28 days
although this diﬀerence seemed to depend on one case
in which the expression decreased remarkably. Even if the
culture conditions for the CD4+ T cells was limited to
a period of around four weeks, four of the six healthy
donors showed a decrease of CXCR3 expression to various
degrees, and it might be concluded that asbestos exposure
potentiates reduction of CXCR3 expression in CD4+ T cells.
On the other hand, the expression of CCR5 varied among all
healthy donors, and there were no signiﬁcant changes afterClinical and Developmental Immunology 5
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Figure 3: Schematic representation of asbestos-induced reduction of expression of a chemokine receptor, CXCR3, and expression and pro-
duction of IFN-γ using the MT-2 cell line model (Org; MT-2 original cell line, and Rst: sublines exposed continuously to a low-dose of
chrysotile), an ex vivo exposure model using freshly isolated CD4+ T cells from healthy donors (HD), as well as analyses of freshly isolated
CD4+ T cells from healthy donors and patients with pleural plaque (PP) and malignant mesothelioma (MM).
seven and 28 days of coculture with chrysotile, as shown
previously by the cell line model. These results indicated that
CXCR3 expression might be speciﬁcally reduced by asbestos
exposure. In addition, these experiments revealed decreased
IFN-γ expression and production when CD4+ T cells from
healthy donors were cultured with chrysotile for 28 days
[52].
Finally, analyses of changes in surface CXCR3 expression
on freshly isolated CD4+ T cells from asbestos-exposed
patients such as PP or MM were compared with those from
healthdonors. Inaddition, IFN-γ expression of CD4+ Tcells
from these patients and healthy donors was measured with
stimulation using anti-CD3/CD28 antibodies with IL-2. As
summarized in Figure 3(c), CXCR3 expression was reduced
in CD4+ T cells from asbestos patients. A comparison of
PP and MM patients showed that the expression level of
CXCR3 on CD4+ T cells from MM was decreased although
thediﬀerencewasnotstatisticallysigniﬁcant.Moreover,IFN-
γ expression was only reduced in stimulated CD4+ T cells
from MM patients, not in those from PP patients [52].
With the ﬁndings that CD4+CXCR3+ T cells in lympho-
cytesfromMMsshowedatendencyforaninversecorrelation
with CXCR3’s ligand, CXCL10/IP10 in plasma, our results
indicate a reduction of tumor immune function in asbestos-
exposed patients and suggest that CXCR3, IFN-γ,a n d
CXCL10/IP10 may be candidates to detect and monitor
disease status.
4. Alteration of NK Cells and Others
As shown in Figure 4, the eﬀects of asbestos on other
immunocompetent cells such as Treg, CD8+ CTL, and
NK cells were investigated. As mentioned above with the
MT-2 cell line model, sublines continuously exposed to
chrysotile showed overproduction of IL-10 and TGF-β.I ti s
well known that these cytokines are a typical soluble factor
produced from Treg to function with a suppressive eﬀect
on activated responder T cells. On the other hand, it is also
reported that MT-2 cells possess a Treg function, since cells
express CD4 and CD25 with nuclear expression of FoxP3.
Taken together, continuous exposure to chrysotile produces
astrongerTregfunction,atleastwiththecapacitytoproduce
soluble functional factors (i.e., IL-10 and TGF-β)[ 47, 48]. At
present, we have been studying alteration of Treg function
using the MT-2 cell line model, and preliminary ﬁndings
indicate asbestos may enhance Treg function.
In regard to tumor immunity, CD8+ CTL and NK cells
are very important players, since they directly kill tumor
cells even when individually restricted with major histocom-
patibility complexes. Investigations have just started with6 Clinical and Developmental Immunology
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CD8+ CTL, but in ex vivo experimental conditions designed
to produce CD8+ CTL proliferation and diﬀerentiation
using freshly isolated peripheral blood mononuclear cells
from healthy donors, the addition of asbestos seems to
result in reduced proliferation and diﬀerentiation of CTL.
Although detailed analyses concerning the roles of cytokines
surrounding CTL diﬀerentiation are being performed, our
ongoing studies suggest that asbestos reduces CTL activities.
Regarding NK cells, cellular and molecular analyses have
been conducted using a human NK cell line, YT-A1, exposed
continuously to asbestos in an ex vivo exposure model using
freshly isolated NK cells from health donors, as well as asbes-
tos-exposed patients such as PP and MM.
Focusing on the NK cell-activating receptors, including
NKG2D (also known as KLRK1 (killer cell lectin-like recep-
tor subfamily K, member 1), klr and CD314, binding to a
diverse family of ligands that include MHC class I chain-
related A and B proteins and UL-16 binding proteins, where
ligand-receptor interactions can result in the activation of
NK and T cells), 2B4 (also known as NAIL; Nmrk; NKR2B4;
SLAMF4 and CD244, mediate nonmajor histocompatibility
complex (MHC) restricted killing), and NKp46 (also known
as NCR1 (natural cytotoxicity triggering receptor 1), LY94
and CD335, constituting a natural cytotoxic receptor family
with NKp44 and NKp30, and being important in killing
tumor cells and dendritic cells), the YT-A1 human NK cell
line exposed continuously to chrysotile asbestos reveal-ed
reduced expression of NKG2D and 2B4 [53]. The reduc-
ed phosphorylation of extracellular signal-regulated kinase
(ERK) and subsequent reduction of degranulation of per-
forin and granzyme B resulting from reduced cytotoxicity
were observed in this cell line model [54]. Similar to the cell
line model, the ex vivo exposure model using freshly isolated
NK cells from healthy donors revealed a reduction of NKp46
expression. Furthermore, freshly isolated NK cells from MM
patients showed reduced killing function compared with
those from healthy donors and revealed a lower expression
of NKp46 [53]. Moreover, the expression level of NKp46,
but not NKG2D or 2B4, and the cytotoxic activity of
individual freshly isolated NK cells from health donors and
MM patients clearly showed a reverse correlation, indicating
that the target molecule of asbestos-induced dysfunction
of NK cells is NKp46 [54]. Although further analyses are
required regarding the interaction between asbestos-exposed
NK cells and other immunocompetent cellssuch as dendritic
cells, monocytes, and macrophages, molecular mechanisms
to reduce NKp46 expression and other aspects need to
be explored, and surface NKp46 expression levels may be
the candidate to monitor the level of tumor immunity in
asbestos-exposed patients [55].
Further investigations are needed to examine the eﬀects
of asbestos exposure on other types of immunocompetent
cells such as Th17 dendritic cells, NKT, and the monocyte-
macrophage lineage, and to investigate why asbestos seems
to reduce tumor immunity in the total network of the im-
munological surveillance system.
In addition, although we have mainly analyzed the
eﬀects of chrysotile asbestos on the human immune system,Clinical and Developmental Immunology 7
diﬀerences and similarities between the diﬀerent types of
ﬁbers should also be investigated.
5. Conclusion
Wehavebeeninvestigatingtheeﬀectsofasbestosexposureon
thehumanimmunesysteminregardtotumorimmunityand
foundthatpeopleexposedtoasbestospossessreducedtumor
immunity, making them sensitive to cancer development.
Although these studies may contribute to the clear recogni-
tion of the biological eﬀects of asbestos, the variety of
alterations in immunocompetent cells may be the factor
that allows detection of previous asbestos exposure and the
occurrence of cancer in people that live or have lived near
asbestos-handling manufacturers. Furthermore, to recover
tumor immunity using physiologically active substances in
f o o d so rd e r i v e df r o mp l a n t sm a yb ea ne ﬀective method for
the chemical prevention of asbestos-induced cancers.
Acknowledgments
The authors specially thank Dr. Masayasu Kusaka (Kusaka
Hospital, 1122 Nishikatagami, Bizen, 705-0121, Japan), Dr.
Kozo Urakami (Hinase Urakami Iin, 243-4 Hinase, Hinase-
cho, Bizen, 701-3204, Japan), Professors Takashi Nakano
and Kazuya Fukuoka (Department of Respiratory Medicine,
Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinom-
iya, 663-8501, Japan), and Drs. Takumi Kishimoto, Rika
Tabata, Kenichi Genma, and Ms. Yoko Kojima (Okayama
Rosai Hospital, 1-10-25, Chikkou Midori-machi, Minami-
ku, Okayama 702-8055, Japan) for their particular contribu-
tion to the organization of patients. They also thank Ms.
Tamayo Hatayama, Yoshiko Yamashita, Minako Kato, Tomo-
ko Sueishi, Keiko Kimura, Misao Kuroki, Naomi Miyahara,
and Shoko Yamamoto for their technical help. The experi-
mentalresultsperformedbytheauthorsandpresentedpartly
in this paper were supported by Special Funds for Pro-
moting Science and Technology (H18-1-3-3-1), JSPS KAK-
ENHI(22790550,22700933,20390178,20890270,19689153,
19790431, 19790411, 18390186, 16390175, and 09670500),
the Takeda Science Foundation (Tokutei Kenkyu Josei I,
2008), and Kawasaki Medical School Project Grants (22-B1,
22-A58, 22-A29, 21-401, 21-201, 21-107, 20-411I, 20-210O,
20-109N, 20-402O, and 20-410I).
References
[1] “Asbestosscandal,”Nature,vol.468,no.7326,868pages,2010.
[2] S. Kumagai and N. Kurumatani, “Mapping the risk of meso-
thelioma due to neighborhood asbestos exposure,” American
Journal of Respiratory and Critical Care Medicine, vol. 178, no.
6, pp. 624–629, 2008.
[3] S. Kumagai and N. Kurumatani, “Asbestos ﬁber concentration
in the area surrounding a former asbestos cement plant and
excess mesothelioma deaths in residents,” American Journal of
Industrial Medicine, vol. 52, no. 10, pp. 790–798, 2009.
[4] S. Kumagai, N. Kurumatani, T. Tsuda, T. Yorifuji, and E.
Suzuki, “Increased risk of lung cancer mortality among resi-
dents near an asbestos product manufacturing plant,” Interna-
tional Journal of Occupational and Environmental Health, vol.
16, no. 3, pp. 268–278, 2010.
[5] T. Yamanaka, F. Tanaka, S. Hasegawa et al., “A feasibility
study of induction pemetrexed plus cisplatin followed by
extrapleural pneumonectomy andpostoperativehemithoracic
radiation for malignant pleural mesothelioma,” Japanese Jour-
nal of Clinical Oncology, vol. 39, no. 3, pp. 186–188, 2009.
[6] S.HasegawaandF.Tanaka,“Malignantmesothelioma:current
status and perspective in Japan and the world,” General Thora-
cic and Cardiovascular Surgery, vol. 56, no. 7, pp. 317–323,
2008.
[7] R. Ohashi, K. Tajima, F. Takahashi et al., “Osteopontin modu-
lates malignant pleural mesothelioma cell functions in vitro,”
Anticancer Research, vol. 29, no. 6, pp. 2205–2214, 2009.
[8] C. Tabata, N. Hirayama, R. Tabata et al., “A novel clinical role
for angiopoietin-1 in malignant pleural mesothelioma,” Euro-
pean Respiratory Journal, vol. 36, no. 5, pp. 1099–1105, 2010.
[9] A. Yasumitsu, C. Tabata, R. Tabata et al., “Clinical signiﬁcance
of serum vascular endothelial growth factor in malignant
pleural mesothelioma,” Journal of Thoracic Oncology, vol. 5,
no. 4, pp. 479–483, 2010.
[10] Y. Okumura, F. Tanaka, K. Yoneda et al., “Circulating tumor
cells in pulmonary venous blood of primary lung cancer pa-
tients,” Annals of Thoracic Surgery, vol. 87, no. 6, pp. 1669–
1675, 2009.
[11] F. Tanaka, K. Yoneda, N. Kondo et al., “Circulating tumor cell
asadiagnosticmarkerinprimarylungcancer,”ClinicalCancer
Research, vol. 15, no. 22, pp. 6980–6986, 2009.
[12] H. Murakami, T. Mizuno, T. Taniguchi et al., “LATS2 is a
tumor suppressor gene of malignant mesothelioma,” Cancer
Research, vol. 71, no. 3, pp. 873–883, 2011.
[13] Y. Sekido, “Inactivation of Merlin in malignant mesothelioma
cells and the Hippo signaling cascade dysregulation,” Pathol-
ogy International, vol. 61, no. 6, pp. 331–344, 2011.
[14] Y. Goto, K. Shinjo, Y. Kondo et al., “Epigenetic proﬁles distin-
guish malignant pleural mesothelioma from lung adenocar-
cinoma,”CancerResearch,vol.69,no.23,pp.9073–9082,2009.
[15] S. Toyokuni, “Mechanisms of asbestos-induced carcinogene-
sis,” Nagoya Journal of Medical Science, vol. 71, no. 1-2, pp. 1–
10, 2009.
[16] S. Toyokuni, “Role of iron in carcinogenesis: cancer as a ferro-
toxic disease,” Cancer Science, vol. 100, no. 1, pp. 9–16, 2009.
[17] Q.Hu,S.Akatsuka,Y.Yamashitaet al.,“Homozygous deletion
of CDKN2A/2B is a hallmark of iron-induced high-grade rat
mesothelioma,” Laboratory Investigation,v o l .9 0 ,n o .3 ,p p .
360–373, 2010.
[18] S. Toyokuni, “Iron as a target of chemoprevention for longe-
vity in humans,” Free Radical Research. In press.
[19] H. Nagai and S. Toyokuni, “Biopersistent ﬁber-induced in-
ﬂammation and carcinogenesis: lessons learned from asbestos
toward safety of ﬁbrous nanomaterials,” Archives of Biochem-
istry and Biophysics, vol. 502, no. 1, pp. 1–7, 2010.
[20] J. E. Craighead, A. I. Gibbs, and F. Pooley, “Mineralogy of
asbestos,” in Asbestos and Its Diseases, J. E. Craighead and A.
R. Gibbs, Eds., pp. 23–38, Oxford University Press, New York,
NY, USA, 2008.
[21] V.L.RoggliandP.Coin,“Mineralogyofasbestos,”inPathology
of Asbestos-Associated Diseases,V .L .R o g g l i ,T .D .O u r y ,a n dT .
A.Sporn,Eds.,pp.1–16,SpringerScienceandBusinessMedia,
New York, NY, USA, 2nd edition, 2004.8 Clinical and Developmental Immunology
[22] C. L. Uber and R. A. McReynolds, “Immunotoxicology of
silica,” Critical Reviews in Toxicology, vol. 10, no. 4, pp. 303–
319, 1982.
[23] K. Steenland and D. F. Goldsmith, “Silica exposure and auto-
immune diseases,” American Journal of Industrial Medicine,
vol. 28, no. 5, pp. 603–608, 1995.
[24] H. Reyes, E. A. Ojo-Amaize, and J. B. Peter, “Silicates, silicones
and autoimmunity,” Israel Journal of Medical Sciences, vol. 33,
no. 4, pp. 239–242, 1997.
[25] D. D’Cruz, “Autoimmune diseases associated with drugs,
chemicals and environmental factors,” Toxicology Letters, vol.
112-113, pp. 421–432, 2000.
[26] M. D. Mayes, “Epidemiologic studies of environmental agents
and systemic autoimmune diseases,” Environmental Health
Perspectives, vol. 107, no. 5, pp. 743–748, 1999.
[27] J. Schreiber, D. Koschel, J. Kekow, N. Waldburg, A. Goette,
and R. Merget, “Rheumatoid pneumoconiosis (Caplan’s syn-
drome),” European Journal of Internal Medicine, vol. 21, no. 3,
pp. 168–172, 2010.
[28] T.Otsuki,Y.Miura,Y.Nishimuraetal.,“AlterationsofFasand
Fas-related molecules in patients with silicosis,” Experimental
Biology and Medicine, vol. 231, no. 5, pp. 522–533, 2006.
[29] T. Otsuki, M. Maeda, S. Murakami et al., “Immunological
eﬀectsofsilicaandasbestos,”CellularandMolecularImmunol-
ogy, vol. 4, no. 4, pp. 261–268, 2007.
[30] P. Wu, Y. Miura, F. Hyodoh et al., “Reduced function of
CD4+25+regulatoryTcellfractioninsilicosispatients,”Inter-
national Journal of Immunopathology and Pharmacology, vol.
19, no. 2, pp. 357–368, 2006.
[31] T. Otsuki, H. Hayashi, Y. Nishimura et al., “Dysregulation
of autoimmunity caused by silica exposure and alteration
of Fas-mediated apoptosis in T lymphocytes derived from
silicosis patients,” International Journal of Immunopathology
and Pharmacology, vol. 24, supplement 1, pp. 11S–16S, 2011.
[32] H. Hayashi, Y. Miura, M. Maeda et al., “Reductive alteration
of the regulatory function of the CD4+CD25+ T cell fraction
insilicosispatients,”InternationalJournalofImmunopathology
and Pharmacology, vol. 23, no. 4, pp. 1099–1109, 2010.
[33] R. Rolston and D. Oury, “Other neoplasia,” in Pathology of
Asbestos-Associated Diseases,V .L .R o g g l i ,T .D .O u r y ,a n dT .
A. Sporn, Eds., pp. 217–230, Springer Science and Business
Media, New York, NY, USA, 2nd edition, 2004.
[34] R. A. Lemen, “Epidemiology of asbestos-related diseases and
the knowledge that led to what is known today,” in Asbestos,
RiskAssessment,Epidemiology,andHealthEﬀects,R.F .Dodson
andS.P.Hammared,Eds.,pp.201–308,CRCPress,Taylorand
Francis Group, Boca Ratton, Fla, USA, 2006.
[35] J. E. Craughea, “Nonthoracic cancers possibly resulting from
asbestos exposure,” in Asbestos and Its Diseases,J .E .C r a i g h e a d
and A. R. Gibbs, Eds., pp. 230–252, Oxford University Press,
New York, NY, USA, 2008.
[36] J. C. Barrett, P. W. Lamb, and R. W. Wiseman, “Multiple
mechanisms for the carcinogenic eﬀects of asbestos and other
mineral ﬁbers,” Environmental Health Perspectives, vol. 81, pp.
81–89, 1989.
[37] J. M. Davis, “Mineral ﬁbre carcinogenesis: experimental data
relating to the importance of ﬁbre type, size, deposition, dis-
solution and migration,” IARC Scientiﬁc Publications, no. 90,
pp. 33–45, 1989.
[38] I. Miyoshi, I. Kubonishi, S. Yoshimoto, and Y. Shiraishi, “A T-
cell line derived from normal human cord-leukocytes by co-
culturing with human leukemic T-cells,” Gann, vol. 72, no. 6,
pp. 978–981, 1981.
[39] I. Miyoshi, I. Kubonishi, S. Yoshimoto et al., “Type C virus
particles in a cord T-cell line derived by co-cultivating normal
humancordleukocytes andhumanleukaemicTcells,”Nature,
vol. 294, no. 5843, pp. 770–771, 1981.
[40] F. Hyodoh, A. Takata-Tomokuni, Y. Miura et al., “Inhibitory
eﬀects of anti-oxidants on apoptosis of a human polyclonal T-
cell line, MT-2, induced by an asbestos, chrysotile-A,” Scandi-
navian Journal of Immunology, vol. 61, no. 5, pp. 442–448,
2005.
[41] G. Liu, R. Beri, A. Mueller, and D. W. Kamp, “Molecular
mechanisms of asbestos-induced lung epithelial cell apopto-
sis,” Chemico-Biological Interactions, vol. 188, no. 2, pp. 309–
318, 2010.
[42] B. Fubini and A. Hubbard, “Reactive oxygen species (ROS)
and reactive nitrogen species (RNS) generation by silica in in-
ﬂammation and ﬁbrosis,” Free Radical Biology and Medicine,
vol. 34, no. 12, pp. 1507–1516, 2003.
[43] D. Upadhyay and D. W. Kamp, “Asbestos-induced pulmonary
toxicity: role of DNA damage and apoptosis,” Experimental
Biology and Medicine, vol. 228, no. 6, pp. 650–659, 2003.
[44] A. Shukla, M. Gulumian, T. K. Hei, D. Kamp, Q. Rahman, and
B. T. Mossman, “Multiple roles of oxidants in the pathogene-
sis of asbestos-induced diseases,” Free Radical Biology and
Medi-cine, vol. 34, no. 9, pp. 1117–1129, 2003.
[45] Y. Miura, Y. Nishimura, H. Katsuyama et al., “Involvement of
IL-10 and Bcl-2 in resistance against an asbestos-induced apo-
ptosis of T cells,” Apoptosis, vol. 11, no. 10, pp. 1825–1835,
2006.
[46] Y. Miura, Y. Nishimura, M. Maeda et al., “Immunological
alterations found in mesothelioma patients and supporting
experimental evidence,” Environmental Health and Preventive
Medicine, vol. 13, no. 2, pp. 55–59, 2008.
[47] S. Murakami, Y. Nishimura, M. Maeda et al., “Cytokine
alteration and speculated immunological pathophysiology in
silicosis and asbestos-related diseases,” Environmental Health
and Preventive Medicine, vol. 14, no. 4, pp. 216–222, 2009.
[48] M. Maeda, Y. Nishimura, N. Kumagai et al., “Dysregulation of
the immune system caused by silica and asbestos,” Journal of
Immunotoxicology, vol. 7, no. 4, pp. 268–278, 2010.
[49] J. Wenzel and T. T¨ uting, “An IFN-associated cytotoxic cellular
immune response against viral, self-, or tumor antigens is a
common pathogenetic feature in ”interface dermatitis”,” Jour-
nal of Investigative Dermatology, vol. 128, no. 10, pp. 2392–
2402, 2008.
[50] R. M. Strieter, M. D. Burdick, J. Mestas, B. Gomperts, M. P.
Keane, and J. A. Belperio, “Cancer CXC chemokine networks
andtumourangiogenesis,”EuropeanJournalofCancer,vol.42,
no. 6, pp. 768–778, 2006.
[51] M. Maeda, Y. Nishimura, H. Hayashi et al., “Reduction of
CXCR3 in an in vitro model of continuous asbestos exposure
onahumanT-cellline,MT-2,”AmericanJournalofRespiratory
Cell and Molecular Biology. In press.
[52] M.Maeda,Y.Nishimura,H.Hayashietal.,“DecreasedCXCR3
expression in CD4+ T cells exposed to asbestos or derived
from asbestos-exposed patients,” American Journal of Respira-
tory Cell and Molecular Biology. In press.
[53] Y. Nishimura, Y. Miura, M. Maeda et al., “Impairment in
cytotoxicity and expression of NK cell-activating receptors on
human NK cells following exposure to asbestos ﬁbers,” Inter-
national Journal of Immunopathology and Pharmacology, vol.
22, no. 3, pp. 579–590, 2009.
[54] Y. Nishimura, M. Maeda, N. Kumagai, H. Hayashi, Y. Miura,
andT.Otsuki,“DecreaseinphosphorylationofERKfollowing
decreasedexpressionofNKcell-activating receptorsinhumanClinical and Developmental Immunology 9
NK cell line exposed to asbestos,” International Journal of
Immunopathology and Pharmacology, vol. 22, no. 4, pp. 879–
888, 2009.
[55] Y.Nishimura,N.Kumagai,M.Maedaetal.,“Suppressiveeﬀect
of asbestos on cytotoxicity of human NK cells,” International
Journal of Immunopathology and Pharmacology, vol. 24, sup-
plement 1, pp. 5S–10S, 2011.